Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer

Show simple item record

dc.contributor.author Mix, M en
dc.contributor.author Ramnath, N en
dc.contributor.author Gomez, J en
dc.contributor.author de Groot, C en
dc.contributor.author Rajan, S en
dc.contributor.author Dibaj, S en
dc.contributor.author Tan, W en
dc.contributor.author Rustum, Y en
dc.contributor.author Jameson, Michael en
dc.contributor.author Singh, AK en
dc.date.accessioned 2017-09-07T02:31:47Z en
dc.date.issued 2015-10 en
dc.identifier.citation World Journal of Clinical Oncology 6(5):156-165 Oct 2015 en
dc.identifier.issn 2218-4333 en
dc.identifier.uri http://hdl.handle.net/2292/35546 en
dc.description.abstract AIM: To prospectively determine the safety and tolerability of oral L-selenomethionine (SLM) with concurrent chemoradiation (CCRT) for Stage III non-small cell lung cancer (NSCLC) and estimate if the incidence and/or severity of adverse events could be reduced by its use. METHODS: Sixteen patients with stage III NSCLC were accrued to this single arm, phase II study. CCRT consisted of radiation given at 2 Gy per fraction for 30-33 fractions, 5 d per week with concurrent weekly IV paclitaxel 50 mg/m(2) followed by carboplatin dosed at an area under the time-concentration curve of 2. SLM was dosed in a loading phase at 4800 mug twice daily for one week prior to CCRT followed by once daily dosing during treatment. RESULTS: No selenium-related toxicity was observed. Analysis revealed grade 3 or higher esophagitis in 3 of 16 patients (19%), pneumonitis in 0, leukopenia in 2 (12.5%), and anemia in 1 (6%); the latter two were significantly reduced when compared to the protocol-stated expected rate of 35% (P = 0.045 for leukopenia, and P < 0.01 for anemia). Median overall survival was 14.9 mo and median failure-free survival was 9 mo (95%CI: 3.3-21.5). CONCLUSION: There may be some protective benefit of selenium in the setting of CCRT for inoperable NSCLC. The data suggests decreased rates of myelosuppression when compared to similarly-treated historical and contemporary controls. Further evaluation of selenium in this setting may be warranted en
dc.publisher Baishideng Publishing Group Co. Limited en
dc.relation.ispartofseries World Journal of Clinical Oncology en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from http://www.sherpa.ac.uk/romeo/issn/2218-4333/ en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.rights.uri https://creativecommons.org/licenses/by-nc/4.0/ en
dc.title Effects of selenomethionine on acute toxicities from concurrent chemoradiation for inoperable stage III non-small cell lung cancer en
dc.type Journal Article en
dc.identifier.doi 10.5306/wjco.v6.i5.156 en
pubs.issue 5 en
pubs.begin-page 156 en
pubs.volume 6 en
dc.description.version VoR - Version of Record en
dc.rights.holder Copyright: The authors en
pubs.end-page 165 en
dc.rights.accessrights http://purl.org/eprint/accessRights/OpenAccess en
pubs.subtype Article en
pubs.elements-id 602893 en
pubs.org-id Medical and Health Sciences en
pubs.org-id School of Medicine en
pubs.org-id Waikato Clinical school en
dc.identifier.eissn 2218-4333 en
pubs.record-created-at-source-date 2016-12-19 en

Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record


Search ResearchSpace